Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Nomathemba Chandiwana and Simiso Sokhela.
Nomathemba Chandiwana
Connection Strength
1,118
Simiso Sokhela
  1. Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens. Open Forum Infect Dis. 2024 Mar; 11(3):ofae007.
    View in: PubMed
    Score: 0,234
  2. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. AIDS. 2021 12 15; 35(Suppl 2):S117-S125.
    View in: PubMed
    Score: 0,202
  3. Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257.
    View in: PubMed
    Score: 0,059
  4. Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans. Pharmacogenet Genomics. 2023 07 01; 33(5):91-100.
    View in: PubMed
    Score: 0,055
  5. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG. Clin Infect Dis. 2023 04 17; 76(8):1492-1495.
    View in: PubMed
    Score: 0,055
  6. Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. CPT Pharmacometrics Syst Pharmacol. 2023 06; 12(6):821-830.
    View in: PubMed
    Score: 0,055
  7. Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV. Pharmacogenet Genomics. 2023 06 01; 33(4):79-87.
    View in: PubMed
    Score: 0,055
  8. Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries. AIDS. 2023 05 01; 37(6):1009-1011.
    View in: PubMed
    Score: 0,055
  9. Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV. South Afr J HIV Med. 2022; 23(1):1452.
    View in: PubMed
    Score: 0,054
  10. Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials. AIDS. 2022 11 01; 36(13):1900-1901.
    View in: PubMed
    Score: 0,054
  11. Pharmacogenetics of dolutegravir plasma exposure among Southern Africans living with HIV. J Infect Dis. 2022 May 04.
    View in: PubMed
    Score: 0,052
  12. Weight gain stopping/switch rules for antiretroviral clinical trials. AIDS. 2021 12 15; 35(Suppl 2):S183-S188.
    View in: PubMed
    Score: 0,050
  13. Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. J Acquir Immune Defic Syndr. 2021 07 01; 87(3):1002-1009.
    View in: PubMed
    Score: 0,049
  14. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 10; 7(10):e666-e676.
    View in: PubMed
    Score: 0,046
  15. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019 08 29; 381(9):803-815.
    View in: PubMed
    Score: 0,043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.